Please do your own research and don't treat this as advice, however please note this drug has received a blockbuster status.
Blockbuster status is defined as a drug that has a mass market appeal and that could earn over $1bn in sales p.a.
This is no small feat, so Eweezy I think you are wrong in that should it pass this phase 2b trial, the stock should go up a lot more.
If it fails, then yes it will plummet but based on real word evidence from TGA patients, this seems like a slim chance of failure.
Fifty One Capital updated report, page-66
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |